In early Wednesday trading, Rapport Therapeutics, Inc. (RAPP), a biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) diseases, saw its stock price tumble 18.8% after completing a $250 million public offering at $26 per share.
The offering is expected to close on September 11, 2025, with the proceeds intended to support the company's growth plans.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.